Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q4 FY2024 Earnings Presentation
26 slides from Zim Laboratories's earnings presentation, May 13, 2024
Slide 1: Exchange filing cover letter for Q4 & FY24 earnings presentation
Ref No.: ZLL/CS/BM/BSE-NSE Date : 13.05.2024 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLA
Slide 2: Innovation and Differentiation for Patient-Centric Solutions: Q4 & FY24 Earnings Presentation
INNOVATION AND DIFFERENTIATION FOR PATIENT-CENTRIC SOLUTIONS Q4 & FY24 – EARNINGS PRESENTATION
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: Business
BUSINESS eal & Inova i Meine
Slide 5: ZIM Labs at a Glance: FY24
ZIM LABS AT A GLANCE : FY24 o Focused on Improving Drug Delivery Using Proprietary Manufacturing Processes o ZIM develops and supplies combination generic products utilizing innovative drug delivery solutions using various in-house technology platforms ₹ 3,674 Mn FY24 Revenue o Sustained R&D Spend o
Slide 6: Highlights: Q4FY24
HIGHLIGHTS : Q4FY24 Business Highlights Financial Highlights Business Update Run Rate continues to Improve o Pharmaceutical business continued to grow in Q4 reaching ₹ 978Mn; a o Total Operating Income grew 22.4% QoQ and by 12% YoY to ₹1,179Mn growth of 38% QoQ and 4% YoY o EBITDA increased to ₹ 172
Slide 7: Highlights: FY24
HIGHLIGHTS : FY24 Business Highlights Financial Highlights Business Update Highest ever Q4 contributes to strong recovery o Pharmaceutical business contribution for FY24 increased to 81% o While financial performance improved over the quarters, the drop in (₹ 2,966 Mn) from 77% in FY23 (₹ 3,082 Mn)
Slide 8: Committed to Core Strategy
COMMITTED TO CORE STRATEGY Pharma : Nutra Mix % Exports Mix % Pharmaceuticals Nutraceuticals Exports Domestic 77% vs 81% F24 23% vs 19% F24 85% vsvs 81% 78% <, F24 77% F24 15% 23% vs 19% <, vs 22% F24 F24 Formulations VS PFI Mix % NIP + OTF Mix % Formulations PFI NIP + OTF Other Products 35% vs -45%
Slide 9: Strategic Priorities
STRATEGIC PRIORITIES Committedto Committed toenhancing improvingBusiness business Mix andand geographic mix Mix Geographic • Product pipeline - Developing NIP products for growth and differentiation Innovative Product • Formulation business - to grow with improved margins Development • Marketing Aut
Slide 10: Quarter Run Rate
QUARTER RUN RATE Total Operating Income (₹ Mn) EBITDA (₹ Mn) & EBITDA Margin 15.6% 15.3% 15.3% 1, 179 14.3% 14.6% 14.1% 13.8% 13.1% 13.1% 12.5% 1,050 1,054 994 1,010 10.1% 963 927 8.8% 867 858 164 172 775 155 161 131 137 126 674 111 114 107 642 65 59 Q1FY22 Q2 Q3 Q4 Q1FY23 Q2 Q3 Q4 Q1FY24 Q2 Q3 Q4 Q
Slide 11: Business Mix
BUSINESS MIX Total Pharma Revenue (₹ Mn) & as % of Total Operating Income Total Nutra Revenue (₹ Mn) & as % of Total Operating Income 95% 93% 33% 89% 86% 86% 83% 80% 77% 77% 75% 74% 26% 25% 67% 23% 23% 20% 17% 14% 310 14% 940 978 11% 245 249 255 807 805 764 761 230 740 708 664 201 613 617 7% 540 5%
Slide 12: Growing Finished Formulations Business
GROWING FINISHED FORMULATIONS BUSINESS Finished Formulation (₹ Mn) & Revenue % Contribution PFI (₹ Mn ) & Revenue % Contribution 52% 46% 70% 68% 44% 42% 60% 60% 61% 40% 58% 59% 51% 38% 57% 37% 36% 36% 54% 53% 35% 29% 44% 27% 540 715 505 646 634 597 433 587 374 403 518 539 502 467 428 289 300 313 255
Slide 13: Continued Contribution from NIP and OTF
CONTINUED CONTRIBUTION FROM NIP AND OTF NIP Revenue (₹ Mn) (NIP + OTF) Revenue (₹ Mn) 372 241 72 73 160 132% 109 112 200% 82 80 47 49 70 FY23 FY24 Q1FY24 Q2FY24 Q3FY24 Q4FY24 FY23 FY24 Q1FY24 Q2FY24 Q3FY24 Q4FY24 OTF Revenue (₹ Mn) 131 o In line with the company strategy, NIP and OTF sale contributi
Slide 14: Geographical Mix: Asia & India Growing
GEOGRAPHICAL MIX : ASIA & INDIA GROWING Business Mix (₹ Mn) Region wise Business Mix (%) Q4FY24 25, 2% 46% 185, 16% 37% 34% 27% 969, 82% 24% 22% 22% Exports India Deemed Exports 18% 15% 14%15% FY23 FY24 12% 246 , 6% 158 , 4% 357 , 9% 646 , 5% 5% 18% 3% Q4FY24 FY23 FY24 3,382 , 2,870 , MENA Asia (Ex
Slide 15: R&D at Core
R&D AT CORE R&D Initiatives R&D Expense Mix % of Total R&D Spend Total R&D Spend as % of Total Operating Income ( ) 6.6% 9.7% • R&D expenses incurred during the year included expenses on 29% 21% new dossiers and BE studies for our EU and Developed market 8% Capital Expenses on BE study, products and
Slide 16: Strong NIP Pipeline to Drive Growth
STRONG NIP PIPELINE TO DRIVE GROWTH Product Therapy Remarks Product 1 Urology Filed in the EU during Q4 FY23, and for other markets thereafter Product 2 Gastro-Intestinal Product 3 Anti - Coagulant Filed in the EU during Q4FY24 Product 4 CNS Product 5 Urology Filings for Registration in EU and Other
Slide 17: Financials
FINANCIALS eal & Inova i Meine
Slide 18: Financial Performance - FY24
FINANCIAL PERFORMANCE - FY24 TotalTotal Operating Income Operating Income(₹(₹Mn) Mn) EBITDA (₹ Mn) & EBITDA % PAT (₹ Mn) & PAT % 8.8% 12.5% 13.1% 14.6% 0.3% 4.8% 5% 6.9% 1,179 172 963 81 858 126 107 41 48 674 59 2 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY24 Q2FY24 Q3FY24 Q4FY24 14
Slide 19: Income Statement
INCOME STATEMENT Change % Change % Particulars (₹ Mn) Q4FY24 Q4FY23 Q3FY24 FY24 FY23 Change % (YoY) (YoY) (QoQ) Total Operating Income 1,179 1,054 12% 963 22.4% 3,674 3,985 (7.8%) Other Income 15 7 119% 11 39.5% 52 64 (19.2%) Total Income 1,194 1,061 12.6% 974 22.6% 3,725 4,049 (8%) EBITDA 172 161 6
Slide 20: Balance Sheet
BALANCE SHEET Particulars (₹ Mn) FY24 FY23 FY22 FY21 Gross Block – Tangible & Intangible Assets including WIP 3,089 2,257 1,920 1,762 Net Block – Tangible & Intangible Assets including WIP 2,031 1,357 1,174 1,172 Other Non- Current Assets 161 150 121 158 Current Assets 2,276 1,909 2,121 1,918 Total
Slide 21: Balance Sheet
BALANCE SHEET Gross and Net Fixed Assets (₹ Mn) Gross Current Assets (GCA) as % of Total Assets 3,086 62% 59% 2,257 2,029 56% 1,762 1,920 1,172 1,174 1,357 51% FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 Net Fixed Assets Gross Fixed Assets GCA % Net Worth (₹ Mn) Total Borrowing (₹ Mn) & Gearing % 50% 45
Slide 22: Corporate
CORPORATE eal & Inova i Meine
Slide 23: Shareholding
SHAREHOLDING Ownership % (On March 24) Traded Volume (In K) BSE+NSE 22,129 41% 18,446 15,690 6,112 5,322 4,950 5,109 4,402 4,034 3,365 1,662 343 15% 3 24 3 23 4 23 3 23 23 3 23 24 l-2 t-2 -2 r-2 -2 p- b- n- g- n- c- v- ar ay Ju Oc Ap 33% No De Se Fe Au Ju Ja M M 4% Shareholders (#) : Q1 - 9k Q2 - 15
Slide 24: Share Price Movement
SHARE PRICE MOVEMENT ZIM (BSE) vs BSE S&P Healthcare Index ZIM (NSE) vs Nifty Healthcare Index 11,837 34,455 11,000 32,699 9,487 10,350 9, 622 9,865 31,549 9, 608 28, 194 8, 550 27,272 8, 317 26, 789 8, 009 23, 681 128 22, 182 123 128 117 118 114 123 115 117 118 114 113 110 111 115 113 110 108 111 1
Slide 25: Q4FY24 Earnings Call Details
Q4FY24 EARNINGS CALL DETAILS Date 15th May, 2024 Time 12 Noon IST Dial – In Details Universal Access Numbers +91-22-62801557/ +91-22-71158383 Diamond Pass Click Here 24
Slide 26: Thank You
Visit ZIM Laboratories Limited: https://www.zimlab.in/ For further information, please get in touch with: ZIM’s Investor Relations Mr. Zain Daud zain.daud@zimlab.in M: +91 9022434631 GoIndia Advisors – IR Firm Ms. Sheetal Khanduja Ms. Deepika Sharma Ms. Priya Sen sheetal@goindiaadvisors.com deepika@